Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Outset Medical (OM) over the last 7 years, with Q3 2025 value amounting to $231000.0.

  • Outset Medical's Cash from Financing Activities rose 9090.91% to $231000.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $55.5 million, marking a year-over-year decrease of 1822.16%. This contributed to the annual value of $55.5 million for FY2025, which is 1822.16% down from last year.
  • According to the latest figures from Q3 2025, Outset Medical's Cash from Financing Activities is $231000.0, which was up 9090.91% from -$384000.0 recorded in Q2 2025.
  • In the past 5 years, Outset Medical's Cash from Financing Activities ranged from a high of $150.8 million in Q2 2021 and a low of -$938000.0 during Q4 2024
  • Its 5-year average for Cash from Financing Activities is $21.1 million, with a median of $2.5 million in 2022.
  • As far as peak fluctuations go, Outset Medical's Cash from Financing Activities soared by 55844814.81% in 2021, and later plummeted by 59870.13% in 2025.
  • Over the past 5 years, Outset Medical's Cash from Financing Activities (Quarter) stood at $934000.0 in 2021, then soared by 6923.55% to $65.6 million in 2022, then crashed by 49.35% to $33.2 million in 2023, then crashed by 102.82% to -$938000.0 in 2024, then soared by 124.63% to $231000.0 in 2025.
  • Its Cash from Financing Activities stands at $231000.0 for Q3 2025, versus -$384000.0 for Q2 2025 and $55.7 million for Q1 2025.